Skip to main content
SpringerLink
Log in

Immunity and Vaccine Development

  • Chapter
Cholera

Part of the book series: Current Topics in Infectious Disease ((CTID))

Abstract

Public health authorities would like to have at their disposal a safe, practical, inexpensive, and highly effective vaccine to provide long-term protection against cholera. The Diarrheal Diseases Control Programme of the World Health Organization has targeted the development of an improved vaccine against cholera as a high priority.1 Such a vaccine to combat cholera is not yet in the public health armamentarium but, as shown in this chapter, several promising candidates are on the horizon.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Diarrhoeal Diseases Control Programme: Biomedical and Epidemiological Research Priorities of Global Scientific Working Groups. WHO/CDD/86.8 Rev.l (1987). Geneva, World Health Organization, 1987.

    Google Scholar 

  2. Goodgame RW, Greenough WB: Cholera in Africa: a message for the West. Ann Inter Med 82: 101–106, 1975.

    Article  CAS  Google Scholar 

  3. Umoh JU, Adesiyun AA, Adekeye JO, et al: Epidemiological features of an outbreak of gastroenteritis/cholera in Katsina, Northern Nigeria. J Hyg (Camb.) 91: 101–111, 1983.

    Article  CAS  Google Scholar 

  4. Ferran J: Nota sobre la profilixas del colera por medio de inyecciones hipodermicas de cultivo puro del bacilo virgula? Siglo Med 32: 480, 1885.

    Google Scholar 

  5. Bornside GH: Jaime Ferran and preventive inoculation against cholera. Bull Hist Med 55: 516–532, 1981.

    PubMed  CAS  Google Scholar 

  6. Koch R: Der zweite Bericht der deutschen Cholera-Commission. Dtsch Med Wochschr 9: 743–744, 1883.

    Google Scholar 

  7. Bornside: GH: Waldemar Haffkine’s cholera vaccines and the Ferran-Haffkine priority dispute. J Hist Med All Sci 37: 399–422, 1982.

    Article  CAS  Google Scholar 

  8. Kolle W: Die aktive Immunisierung des Menschen gegen Cholera nach Haffkine’s Verfahren in Indien. Zbl Bakt I Abt Orig 19: 217–221, 1896.

    Google Scholar 

  9. Voges O: Die Cholera-Immunitat. Zbl Bakt I Abt Orig 19: 325–241, 395.-400, 444-470, 1896.

    Google Scholar 

  10. Haffkine WM: Les vaccinations anticholeriques aux Indes. Bull Inst Pasteur 4: 697–705, 737.-747, 1906.

    Google Scholar 

  11. Haffkine, WM: Protective inoculation against cholera, Calcutta. C R Soc Biol (Paris) 4: 635–671, 1985.

    Google Scholar 

  12. Cvjetanovic B: Contribution of Haffkine to the concept and practice of controlled field trials. Fortschr Arzneimittforsch 19: 481–489, 1975.

    CAS  Google Scholar 

  13. Kolle W: Zur aktiven Immunisierung des Menschen gegen Cholera. Zbl Bakt I Abt Orig 19: 97–104, 1896.

    Google Scholar 

  14. Murata N: Uber die Schutzimpfung gegen Cholera. Zbl Bakt I Abt Orig 35: 605–608, 1904.

    Google Scholar 

  15. Sawtschenko J, Sabolotny DK: Versuch einer Immunisation des menschen gegen Cholera. Zbl allg Path Path Anat 4: 625–636, 1893.

    Google Scholar 

  16. Russell AJH: Besredka’s cholera bilivaccin versus anti-cholera vaccine: a comparative field test, in: Transactions of the Seventh Congress of the Far Eastern Association of Tropical Medicine, 1927, Calcutta, Vol 1. p 253.

    Google Scholar 

  17. Russell AJH: Le bilivaccin anticholerique et le vaccin anticholerique ordinaire. Essai de comparaison pratique, in: Graham JD, Recherhes sur le choiera et la vaccination anticholerique dans l’Inde Brittanique. Bull Off Int Hyg Publ 20: 703–709, 1928.

    Google Scholar 

  18. Russell AJH: Cholera in India, in: Transactions of the Ninth Congress of the Far Eastern Association of Tropical Medicine, 1934, Nanking, Vol 1. p 398.

    Google Scholar 

  19. Sarramon: Sur l’emploi du vaccin anticholerique psr voie buccale. Bull Soc Med-Chir Indochine 8: 180–183, 1930.

    Google Scholar 

  20. Cash RA, Music SI, Libonati JP, et al: Response of man to infection with Vibrio cholerae. Protection from illness afforded by previous disease and vaccine. J Infect Dis 130: 325–333, 1974.

    Article  PubMed  CAS  Google Scholar 

  21. Levine MM, Nalin DR, Craig JP, et al: Immunity to cholera in man: relative role of antibacterial versus antitoxic immunity. Trans Roy Soc Trop Med Hyg 73: 3–9, 1979.

    Article  PubMed  CAS  Google Scholar 

  22. Levine MM: Immunity to cholera as evaluated in volunteers, in Ouchterlony O, Holmgren J (ed): Cholera and Related Diarrheas. Basel, S. Karger, 1980, pp 195-203.

    Google Scholar 

  23. Levine MM, Black RE, Clements ML, et al: Volunteer studies in development of vaccines against cholera and enterotoxigenic Escherichia coli: a review, in Holme T, Holmgren J, Merson M, Mollby R (eds): Acute Enteric Infections in Children: New Prospects for Treatment and Prevention. Amsterdam, Elsevier/North Holland, 1981.

    Google Scholar 

  24. Levine MM, Black RE, Clements ML, et al: The quality and duration of infection-derived immunity to cholera. J Infect Dis 143: 818–820, 1981.

    Article  PubMed  CAS  Google Scholar 

  25. Levine, MM, Kaper JB, Black RE, et al: New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 47: 510–550, 1983.

    PubMed  CAS  Google Scholar 

  26. Shedlofsky S, Freter R: Synergism between ecologic and immunologic control mechanism. J Infect Dis 129: 296–303, 1974.

    Article  PubMed  CAS  Google Scholar 

  27. Woodward WE: Cholera reinfection in man. J Infect Dis 123: 61–66, 1971.

    Article  PubMed  CAS  Google Scholar 

  28. Glass RI, Becker S, Huq MI, et al: Endemic cholera in rural Bangladesh, 1966–1980. Am J Epidemiol 116: 959–970, 1982.

    PubMed  CAS  Google Scholar 

  29. Glass RI, Svennerholm A-M, Stoll B, et al: Protection against cholera in breast-fed children by antibodies in breast milk. N Eng J Med 308: 1389–1392, 1983.

    Article  CAS  Google Scholar 

  30. Glass RI, Svennerholm A-M, Khan RN, et al: Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236–242, 1985.

    Article  PubMed  CAS  Google Scholar 

  31. Benenson AS: Review of experience with whole-cell and somatic antigen cholera vaccines, in: Symposium on Cholera, Sapporo, 1976. US-Japan Cooperative Medical Science Program, National Institute of Health, Tokyo, 1977, pp 228–252.

    Google Scholar 

  32. FeeleyJC, Gangarosa EJ: Field trials of cholera vaccine, in Cholera and Related Diarrheas, 43rd Nobel Symposium, Stockholm, 1978. Basel, Karger, 1980, pp 204-210.

    Google Scholar 

  33. Joo I: Cholera vacines, in Barua D, Burrows W (eds): Cholera. Philadelphia, WB Saunders, 1974, pp 333–335.

    Google Scholar 

  34. Oseasohn RO, Benenson AS, Fahimuddin Md: Field trial of cholera vaccine in rural East Pakistan. Lancet i: 450–453, 1965.

    Article  Google Scholar 

  35. Benenson AS, Mosley WH, Fahimuddin M, et al: Cholera vaccine field trials in East Pakistan. 2. Effectiveness in the field. Bull WHO 38: 359–372, 1968.

    PubMed  CAS  Google Scholar 

  36. Mosley WH, McCormack WM, Ahmed A, et al: Report of the 1966-67 cholera field trial in rural East Pakistan. 2. Results of the serological surveys in the study population—the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull WHO 40: 187–197, 1969.

    PubMed  CAS  Google Scholar 

  37. Mosley WH: The role of immunity in cholera. A review of epidemiological and serological studies. Texas Rep Biol Med 27 (l): 227–244, 1969.

    Google Scholar 

  38. Mosley WH, McCormack WM, Ahmed A, et al: Report of the 1966–67 cholera vaccine field trial in rural East Pakistan. 1. Study design and results of the first year of observation. Bull WHO 40: 177–185, 1969.

    PubMed  CAS  Google Scholar 

  39. Mosley WH, Woodward WE, Aziz KMS, et al: The 1968-1969 cholera vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J Infect Dis 121:S1–S9, 1970.

    Article  Google Scholar 

  40. Mosley, WH, Aziz KMS, Mizanur Rahman ASM, et al: Report of the 1966–67 cholera vaccine trial in rural East Pakistan. Bull WHO 47: 229–238, 1972.

    PubMed  CAS  Google Scholar 

  41. Mosley WH, Aziz KMS, Mizanur Rahman ASM, et al: Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh—three years of observation. Bull WHO 49: 381–387, 1973.

    PubMed  CAS  Google Scholar 

  42. Philippines Cholera Committee: A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull WHO 32: 603–625, 1965.

    Google Scholar 

  43. Azurin JC, Cruz A, Pesigan TP, et al: A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull WHO 37: 703–727, 1967.

    PubMed  CAS  Google Scholar 

  44. Philippines Cholera Committee: A controlled field trial of the effectiveness of various doses of cholera El Tor Vaccine in the Philippines. Bull WHO 38: 917–923, 1968.

    Google Scholar 

  45. Das Gupta A, Sinha R, Shrivastava DL, et al: Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta. Bull WHO 37: 371–385, 1967.

    PubMed  CAS  Google Scholar 

  46. Pal SC, Deb BC, Sen Gupta PG, et al: A controlled field trial of an aluminum phosphate-adsorbed cholera vaccine in Calcutta. Bull WHO 58: 741–745, 1980.

    PubMed  CAS  Google Scholar 

  47. Saroso JS, Bahrawi W, Witjaksono H, et al: A controlled field trial of plain and aluminum hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia, during 1973–75. Bull WHO 56: 619–627, 1978.

    PubMed  CAS  Google Scholar 

  48. Clemens JD, Sack DA, Harris JR, et al: Field trial of oral cholera vaccines in Bangladesh. Lancet ii: 124–127, 1986.

    Article  Google Scholar 

  49. Freter R: Studies on the mechanism of action of intestinal antibody in experimental cholera. Texas Rep Exp Biol Med 27: 299–316, 1969.

    Google Scholar 

  50. Neoh SH, Rowley D: Protection of infant mice against cholera by antibodies to three Vibrio cholerae antigens. J Infect Dis 126: 41–47, 1972.

    Article  PubMed  CAS  Google Scholar 

  51. Fubara ES, Freter R: Protection against enteric infection by secretory antibodies. J Immunol 111: 395–403, 1973.

    PubMed  CAS  Google Scholar 

  52. Bellamy JEC, Knop EJ, Steele EJ, et al: Antibody cross-linking as a factor in immunity to cholera in infant mice. J Infect Dis 132: 181–188, 1975.

    Article  PubMed  CAS  Google Scholar 

  53. Steele EJ, Chaicumpa W, Rowley D: Further evidence for cross-linking as a protective factor in experimental cholera: properties of antibody fragments. J Infect Dis 132: 175–180, 1975.

    Article  PubMed  CAS  Google Scholar 

  54. Guentzel MN, Field LH, Eubanks ER, et al: Use of flourescent antibody in studies of immunity to cholera in infant mice. Infect Immun 15: 539–548, 1977.

    PubMed  CAS  Google Scholar 

  55. Eubanks ER, Guentzel MN, Berry LJ: Evaluation of surface components of Vibrio cholerae as protective immunogens. Infect Immun 15: 533–538, 1977.

    PubMed  CAS  Google Scholar 

  56. Yancey RJ, Willis DL, Berry LJ: Flagella-induced immunity against experimental cholera in adult rabbits. Infect Immun 25: 220–228, 1979.

    PubMed  CAS  Google Scholar 

  57. Hranitsky KW, Mulholland A, Larson AD, et al: Characterization of a flagellar sheath protein of Vibrio cholerae. Infect Immun 27: 597–603, 1980.

    Google Scholar 

  58. Chaicumpa W, Atthasisishtha N: Study of intestinal immunity against V. cholerae: role of antibody to V. cholerae haemagglutinin in intestinal immunity. SE Asian J Trop Med Publ Hlth 8: 13–18, 1977.

    CAS  Google Scholar 

  59. Fujita K, Finkelstein RA: Antitoxic immunity in experimental cholera: comparison of immunity induced perorally and parenterally in mice. J Infect Dis 125: 647–655, 1972.

    Article  PubMed  CAS  Google Scholar 

  60. Holmgren J, Svennerholm A-M, Ouchterlony O, et al: Antitoxic immunity in experimental cholera: protection and serum and local antibody responses in rabbits after enteric and parenteral immunization. Infect Immun 12: 463–470, 1975.

    Google Scholar 

  61. Pierce, NF, Sack RB, Sircar BK: Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral toxoid administration to dogs. J Infect Dis 135: 888–896, 1977.

    Article  PubMed  CAS  Google Scholar 

  62. Pierce NF, Reynolds HY: Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J Immunol 113: 1017–1023, 1974.

    PubMed  CAS  Google Scholar 

  63. Pierce NF, Cray WC Jr, Sircar BK: Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera. Infect Immun 21: 185–193, 1978.

    PubMed  CAS  Google Scholar 

  64. Lange S, Hansson H-A, Molin S-O, et al: Local cholera immunity in mice: intestinal antitoxin-containing cells and their correlation with protective immunity. Infect Immun 23: 743–750, 1979.

    PubMed  CAS  Google Scholar 

  65. Svennerholm A-M, Lange S, Holmgren J: Correlation between intestinal synthesis of specific immunoglobulin A and protection against experimental cholera in mice. Infect Immun 21: 1–6, 1978.

    PubMed  CAS  Google Scholar 

  66. Pierce NF, Cray WC Jr, Engel PF: Antitoxic immunity to cholera in dogs immunized orally with cholera toxin. Infect Immun 27: 632–637, 1980.

    PubMed  CAS  Google Scholar 

  67. Pierce NF, Cray WC Jr, Sacci JB Jr: Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms. Infect Immun 37: 687–694, 1982.

    PubMed  CAS  Google Scholar 

  68. Peterson JW: Protection against experimental cholera by oral or parenteral immunization. Infect Immun 26: 594–598, 1979.

    PubMed  CAS  Google Scholar 

  69. Pierce, NF, Cray WC Jr, Sacci JB Jr, et al: Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. Infect Immun 40: 1112–1118, 1983.

    PubMed  CAS  Google Scholar 

  70. Svennerholm A-M, Holmgren J: Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun 13: 735–740, 1976.

    PubMed  CAS  Google Scholar 

  71. Holmgren J, Svennerholm A-M: Mechanisms of disease and immunity in cholera: a review. J Infect Dis 136:S105–S112, 1977.

    Article  PubMed  Google Scholar 

  72. Peterson JW: Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine. Infect Immun 26: 528–533, 1979.

    PubMed  CAS  Google Scholar 

  73. Resnick IG, Ford CW, Shackleford GM, et al: Improved protection against cholera in adult rabbits with a combined flagellar-toxoid vaccine. Infect Immun 30: 375–380, 1980.

    PubMed  CAS  Google Scholar 

  74. Chaicumpa W, Boonthum A, Kalumbaheti T, et al. Cell-bound haemagglutinin (CHA) of V. cholerae 01 as protective antigen. SE Asian J Trop Med Publ Hlth 15: 407–413, 1984.

    CAS  Google Scholar 

  75. Levine MM, Kaper JB, Herrington D, et al: Deletion mutants of Vibrio cholerae 01 prepared by recombinant techniques: insights on pathogenesis and immunity. Infect Immun 1988: in press.

    Google Scholar 

  76. Black RE, Levine MM, Clements ML, et al: Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun 55: 1116–1120, 1987.

    PubMed  CAS  Google Scholar 

  77. Kaper JB, Lockman H, Baldini M, et al: Recombinant nontoxigenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature 308: 655–658, 1984.

    Article  PubMed  CAS  Google Scholar 

  78. Curlin G, Levine R, Aziz KMS, et al: Field trial of cholera toxoid, in: Proceedings of the 11th Joint Conference on Cholera. U.S.-Japan Cooperative Medical Science Program, 1975, pp 314-329.

    Google Scholar 

  79. Noriki H: Evaluation of toxic field trial on the Philippines, in Fukumi H, Zinnaka Y (eds): Proceedings of the 12th Joint Conference on Cholera, U.S.-Japan Cooperative Medical Science Program. Sapporo. Fuji, Tokyo, 1976, pp 302-310.

    Google Scholar 

  80. Clemens JD, Harris JR, Sack DA, et al: Field trial of oral cholera vaccines in Bangladesh: results of one year follow-up. J Infect Dis 158: 60–69, 1988.

    Article  PubMed  CAS  Google Scholar 

  81. Clemens JD, Sack DA, Harris Jr, et al: Field trial of oral cholera vaccines in Bangladesh: results from three year follow-up. Lancet 335: 270–273, 1990.

    Article  PubMed  CAS  Google Scholar 

  82. Clemens JD, Sack DA, Harris JR, et al: Cross-protection by B subunit-whole cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158: 372–377, 1988.

    Article  PubMed  CAS  Google Scholar 

  83. Neoh SE, Rowley D: The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J Infect Dis 121: 505–513, 1970.

    Article  PubMed  CAS  Google Scholar 

  84. Kaur J, Burrows W: Immunity to cholera: relation of fraction II of type 2 cholera toxin to vibriocidal. J Bacteriol 98: 467-474.

    Google Scholar 

  85. Attridge SR, Rowley D: Prophylactic significance of the nonpolysaccharide antigens of Vibrio cholerae. J Infect Dis 148: 931–939, 1983.

    Article  PubMed  CAS  Google Scholar 

  86. Ahmad A, Bhattacharjee AK, Mosley WH: Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and normal residents of the endemic and non-endemic cholera areas. J Immunol 105: 431–441, 1970.

    Google Scholar 

  87. Merritt CB, Sack RB: Sensitivity of agglutinating and vibriocidal antibodies to 2-mercaptoethanol in human cholera. J Infect Dis 121:S25-S30.

    Google Scholar 

  88. Majumdar AS, Ghose AC: Evaluation of the biological properties of different classes of human antibodies in relation to cholera. Infect Immun 32: 9–14, 1981.

    PubMed  CAS  Google Scholar 

  89. Clements ML, Levine MM, Young CR, Black RE, Lim Y-L, Robins-Browne RM: Magnitude, kinetics and duration of vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae. J Infect Dis 145: 465–473, 1982.

    Article  PubMed  CAS  Google Scholar 

  90. Tomasi TB: The Immune System of Secretions. Englewood Cliffs, NJ, Prentice-Hall, 1976.

    Google Scholar 

  91. Waldman RH, Bencic Z, Sakazaki R, et al: Cholera immunology. II. Serum and intestinal secretion antibody response after naturally-occurring cholera. J Infect Dis 126: 401–407, 1972.

    Article  PubMed  CAS  Google Scholar 

  92. Champsur H, Iscaki S, Bernard, et al: Induction of Vibrio cholerae specific biliary antibodies after oral immunization with a cholera cell wall fraction. Lancet i: 1276–1277, 1985.

    Article  Google Scholar 

  93. Estavoyer JM, Panouse-Perrin J, Dodin A, et al: La maladie cholerique: etude serologiques d’un cas. Bull Soc Path Ex 75: 242–247, 1982.

    CAS  Google Scholar 

  94. Chaicumpa W, Rowley D: Experimental cholera in infant mice: protective effects of antibody. J Infect Dis 125: 480–485, 1972.

    Article  PubMed  CAS  Google Scholar 

  95. Freter R, Jones GW: Adhesive properties of Vibrio cholerae: nature of the interaction with intact mucosal surfaces. Infect Immun 14: 246–256, 1976.

    PubMed  CAS  Google Scholar 

  96. Chitnis DS, Sharma KD, Kamat RS: Role of somatic antigen of Vibrio cholerae in adhesion to intestinal mucosa. J Med Microbiol 5: 53–61, 1982.

    Article  Google Scholar 

  97. Benenson AS, Saad A, Mosley WH, et al: Serological studies in cholera. 3. Serum toxin neutralization—Rise in titre in response to infection with Vibrio cholerae, and the level in the “normal” population of East Pakistan. Bull WHO 38: 287–295, 1968.

    PubMed  CAS  Google Scholar 

  98. Levine MM, Young CR, Hughes TP, et al: Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology. Am J Epidemiol 114: 348–354, 1981.

    PubMed  CAS  Google Scholar 

  99. Levine MM, Young CR, Black RE, et al: Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol 21: 174–179, 1985.

    PubMed  CAS  Google Scholar 

  100. Svennerholm A-M, Jertborn M, Gothefors L, et al: Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit whole cell vaccine. J Infect Dis 149: 884–893, 1984.

    Article  PubMed  CAS  Google Scholar 

  101. Taylor R, Miller VL, Furlong DB, et al: Use of phoA gene fusions to identity a pilus colonization factor coordinately regulated with cholera toxin. Proc Nat Acad Sci USA 84: 2833–2837, 1987.

    Article  PubMed  CAS  Google Scholar 

  102. Miller VL, Mekalanos JJ: Synthesis of cholera toxin is positively regulated at the transcriptional level by toxR. Proc Nat Acad Sci USA 81: 3471–3475, 1984.

    Article  PubMed  CAS  Google Scholar 

  103. Hall R, Vial PA, Kaper JB, et al: Morphological studies on fimbriae expressed by Vibrio cholerae 01. Microbial Path 4: 257–265, 1988.

    Article  Google Scholar 

  104. Herrington DA, Hall RH, Losonsky G, et al: Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168: 1487–1492, 1988.

    Article  PubMed  CAS  Google Scholar 

  105. Taylor RK, Shaw C, Peterson K, et al: Safe, live Vibrio cholerae vaccines? Vaccines 6: 151–154, 1988.

    Article  CAS  Google Scholar 

  106. Mestecky J, McGhee JR: Immunoglobulin A (IgA) molecular and cellular interaction involved in IgA biosynthesis and immune response. Adv Immunol 40: 153–245, 1987.

    Article  PubMed  CAS  Google Scholar 

  107. Pierce NF, Gowans: Cellular kinetics of the intestinal immune response to cholera toxoid in rats. J Exp Med 142: 1550–1563, 1975.

    Article  PubMed  CAS  Google Scholar 

  108. Weisz-Carrington P, Roux ME, Mc Williams M, et al: Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J Immunol 123: 1705-1708.

    Google Scholar 

  109. Strober W, Hanson LA, Sell KW: Recent Advances in Mucosal Immunity. New York, Raven Press, 1982.

    Google Scholar 

  110. Jertborn M, Svennerholm A-M, Holmgren J: Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine. Int Archs Allergy Appl Immun 75: 38–43, 1984.

    Article  CAS  Google Scholar 

  111. Jertborn M, Svennerholm A-M, Holmgren J: Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol 24: 203–209, 1986.

    PubMed  CAS  Google Scholar 

  112. Majumdar AS, Dutta P, Dutta D, et al: Antibacterial and antitoxin responses in the serum and milk of cholera patients. Infect Immun 32: 1–8, 1981.

    PubMed  CAS  Google Scholar 

  113. Lange S, Vygren H, Svennerholm A-M, et al: Antitoxic cholera immunity in mice. Influence of antigen deposition on antitoxin-containing cells and protective immunity in different parts of intestine. Infect Immun 28: 17–23, 1980.

    PubMed  CAS  Google Scholar 

  114. Pierce NF: The role of antigen form and function in the primary and secondary intestinal immune responses to cholera toxin and toxoid in rats. J Exp Med 148: 195–206, 1978.

    Article  PubMed  CAS  Google Scholar 

  115. Lycke N, Holmgren J: Intestinal mucosal memory and presence of memory cells in lamina proporia and Peyer’s patches in mice 2 years after oral immunization with cholera toxin. Scand J Immunol 23: 611–616, 1986.

    Article  PubMed  CAS  Google Scholar 

  116. Svennerholm A-M, Gothefors L, Sack DA, et al: Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. Bull WHO 62: 909–918, 1984.

    PubMed  CAS  Google Scholar 

  117. Svennerholm A-M, Hanson LA, Holmgren J, et al: Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect Immun 30: 427–430, 1980.

    PubMed  CAS  Google Scholar 

  118. Levine MM, Black RE, Clements ML, et al: Prevention of enterotoxigenic Escherichia coli diarrheal infection by vaccines that stimulate anti-adhesion (anti-pili) immunity, in Boedeker EC (ed): Attachment of Organisms to the Gut Mucosa, Boca Raton, CRC Press, 1984, pp 223–244.

    Google Scholar 

  119. Yardley JM, Keren DF, Hamilton SR, et al: Local (immunoglobulin A) immune responses by the intestine to cholera toxin and its partial suppression by combined systemic and intra-intestinal immunization. Infect Immun 19: 589–597, 1978.

    PubMed  CAS  Google Scholar 

  120. Pierce NF, Koster FT: Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats. J Immunol 124: 307–311, 1980.

    PubMed  CAS  Google Scholar 

  121. Philippines Cholera Committee: A controlled field trial of the effectiveness of monovalent classical and El Tor cholera vaccines in the Philippines. Bull WHO 49: 13–19, 1973.

    Google Scholar 

  122. Northrup RS, Chisari FV: Response of monkeys to immunization with cholera toxoid, toxin, and vaccine: reversion of cholera toxoid. J Infect Dis 125: 471–479, 1972.

    Article  PubMed  CAS  Google Scholar 

  123. Black RE, Yunus Md, Eusof A, et al: Report and immunogenicity of Wellcome cholera toxoids in Bangladeshi volunteers. International Centre for Diarrhoeal Disease Research, Bangladesh, Scientific Report No. 29, Dacca, 1979.

    Google Scholar 

  124. Merson MN, Black RE, Sack DA, et al: Maternal cholera immunisation and secretory IgA in breast milk. Lancet i: 931–932, 1980.

    Article  Google Scholar 

  125. Ohtomo N: Safety and potency tests of cholera toxoid lot 11 in animals and volunteers, in Fukumi H, Zinnaka Y (eds): Proceedings of the 12th Joint Conference on Cholera. US-Japan Cooperative Medical Science Program, Sapporo, Fuji, Tokyo, 1976, pp 286-296.

    Google Scholar 

  126. Rappaport RS, Pierzchala WA, Bonde G, et al: Development of a purified cholera toxin. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen. Infect Immun 14: 687–693, 1976.

    PubMed  CAS  Google Scholar 

  127. Finkelstein RA, Fujita K, Lospallutto JJ: Procholeragenoid: an aggregated intermediate in the formation of choleragenoid. J Immunol 107: 1043–1051, 1971.

    PubMed  CAS  Google Scholar 

  128. Germanier R, Furer E, Varallyay S, et al: Preparation of a purified antigenic cholera toxoid. Infect Immun 13: 1692–1698, 1976.

    PubMed  CAS  Google Scholar 

  129. Germanier R, Furer E, Varallyay S, et al: Antigenicity of cholera toxoid in humans. J Infect Dis 135: 512–516, 1977.

    Article  PubMed  CAS  Google Scholar 

  130. Holmgrem J, Svennerholm A-M, Lonnroth I, et al: Development of an improved cholera vaccine based on subunit toxoid. Nature 269;602–604, 1977.

    Article  Google Scholar 

  131. Holmgren J: Actions of cholera toxin and the prevention and treatment of cholera. Nature 292: 413–417, 1981.

    Article  PubMed  CAS  Google Scholar 

  132. Svennerholm A-M, Sack DA, Holmgren J, et al: Intestinal antibody responses after immunisation with cholera B subunit. Lancet i: 305–308, 1982.

    Article  Google Scholar 

  133. Freter R: Detection of coproantibody and its formation after parenteral and oral immunization of human volunteers. J Infect Dis 111: 37–48, 1962.

    Article  CAS  Google Scholar 

  134. Freter R, Gangarosa EJ: Oral immunization and production of coproantibody in human volunteers. J Immunol 91: 724–729, 1963.

    PubMed  CAS  Google Scholar 

  135. Ganguly R, Clem LW, Benck Z, et al: Antibody response in the intestinal secretions of volunteers immunized with various cholera vaccines. Bull WHO 52: 323–330, 1975.

    PubMed  CAS  Google Scholar 

  136. Denchev V, Jeleva M, Duncheve St: Human immunization with killed cholera vaccine. Acta Microbiol Acad Sci Hung 21: 209–212, 1974.

    PubMed  CAS  Google Scholar 

  137. Oberdoerster F, Thilo W: A new inactivated oral cholera vaccine. Acta Microbiol Acad Sci Hung 21: 213–215, 1974.

    PubMed  CAS  Google Scholar 

  138. Clemens JD, Jertborn M, Sack DA, et al: Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole cell cholera vaccine. J Infect Dis 154: 175–178, 1986.

    Article  PubMed  CAS  Google Scholar 

  139. Dodin A, Plawecki M: Étude sur l’animal de fractions antigeniques radio-actives isoless de V. cholerae. I. La fraction de Ch 1 + 2. Bull Soc Path Ex 71: 22–33, 1977.

    Google Scholar 

  140. Dodin A: Les antigenes vaccinants. Bordeaux Medical 2: 299–301, 1979.

    Google Scholar 

  141. Dodin A: Un vaccin oral contre le cholera. A Recherche 110: 468–469, 1980.

    Google Scholar 

  142. Gateff C, Dodin A, Wiart J: Comparaison des reactions serologiques induites par un vaccine anticholerique classique et une fraction vaccinante purifiée associés ou non au vaccin anti-amaril. Ann Microbiol 126A:231–246, 1975.

    Google Scholar 

  143. Dodin A, Masengo B, Loucq C: Resultats controles du vaccin anticholerique oral de l’Institut Pasteur au cours de l’épidemie du Shaba-Zaire en 1983. C.R. Acad Sci Paris serie III 299: 205–207, 1984.

    CAS  Google Scholar 

  144. Levine MM, Hughes, TP, Young CR, et al: Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally. Infect Immun 21: 158–162, 1978.

    PubMed  CAS  Google Scholar 

  145. Sanyal S, Mukerjee S: Live oral cholera vaccine: report of a trial on human volunteer subjects. Bull WHO 40: 503–511, 1969.

    PubMed  CAS  Google Scholar 

  146. Cash RA, Music SI, Libonati JP, et al: Live oral cholera vaccine: evaluation of the clinical effectiveness of two strains in humans. Infect Immun 10: 762–764, 1974.

    PubMed  CAS  Google Scholar 

  147. Levine MM, Black RE, Clements ML, et al: The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup 01 biotype El Tor isolated from sewage water in Brazil. J Infect Dis 145: 296–299, 1982.

    Article  PubMed  CAS  Google Scholar 

  148. Finkelstein RA, Vasil ML, Holmes RD: Studies on toxigenesis in Vibrio cholerae. l. Isolation of mutants with altered toxigenicity. J Infect Dis 129: 117–123, 1974.

    Article  PubMed  CAS  Google Scholar 

  149. Holmes RK, Vasil ML, Finkelstein RA: Studies on toxigenesis in Vibrio cholerae. III. Characterization of nontoxigenic mutants in vitro and in experimental animals. J Clin Invest 55: 551–560, 1975.

    Article  PubMed  CAS  Google Scholar 

  150. Woodward WE, Gilman RH, Hornick RB, et al: Efficacy of a live oral cholera vaccine in human volunteers. Dev Biol Stand 33: 108–112, 1976.

    PubMed  CAS  Google Scholar 

  151. Honda T, Finkelstein RA: Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc Natl Acad Sci USA 76: 2052–2056, 1979.

    Article  PubMed  CAS  Google Scholar 

  152. Levine MM, Black RE, Clements ML, et al: Evaluation in man of attenuated Vibrio cholerae El Tor Ogawa strain Texas-Star SR as live oral vaccine. Infect Immun 43: 515–522, 1984.

    PubMed  CAS  Google Scholar 

  153. Mekelanos JJ, Moseley SL, Murphy JR, et al: Isolation of enterotoxin structural gene deletion mutations in Vibrio cholerae induced by two mutagenic vibriophages. Proc Natl Acad Sci USA 79: 151–155, 1982.

    Article  Google Scholar 

  154. Manning PA, Heuzenroeder MW, Yeadon J, et al: Molecular cloning and expression in Escherichia coli K-12 of the O antigens of the Inaba and Ogawa serotypes of the Vibrio cholerae 01 lipolysaccharides and their potential for vaccine development. Infect Immun 53: 272–277, 1986.

    PubMed  CAS  Google Scholar 

  155. Wahdan MH, Serie C, Germanier R, et al: A controlled field trial of live oral typhoid vaccine Ty21a. Bull WHO 58: 469–474, 1980.

    PubMed  CAS  Google Scholar 

  156. Levine MM, Ferreccio C, Black RE, et al: Large-scale field trial of Ty21a typhoid vaccine in enteric-coated capsule formulation. Lancet i: 1049–1052, 1987.

    Article  Google Scholar 

  157. Levine MM, Herrington D, Murphy J, et al: Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541 Ty and 543 Ty, as live oral vaccines in human. J Clin Invest 79: 888–902, 1987.

    Article  PubMed  CAS  Google Scholar 

  158. Kaper JB, Lockman H, Baldini MM, et al: Recombinant live oral cholera vaccine. Biotechnology 2: 345–349, 1984.

    Article  CAS  Google Scholar 

  159. Mekalanos JJ, Swartz DJ, Pearson GDN, et al: Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 306: 551–557, 1983.

    Article  PubMed  CAS  Google Scholar 

  160. Levine MM, Black RE, Clements ML, et al: Present status of cholera vaccines. Biochem Soc Trans 12: 200–202, 1984.

    PubMed  CAS  Google Scholar 

  161. Levine MM, Kaper JB, Black RE, et al: Landmarks on the road toward a live oral attenuated cholera vaccine, in Takeda Y (ed): Vibrio cholerae and Cholera. Tokyo, KTK Scientific Publishers, 1988 pg 155–161.

    Google Scholar 

  162. Levine MM, Kaper JB, Herrington D, et al: Volunteer studies of deletion mutants of Vibrio cholerae 01 prepared by recombinant techniques. Infect Immun 56: 161–167, 1988.

    PubMed  CAS  Google Scholar 

  163. Kaper JB, Levine MM, Lockman H, et al: Development and testing of recombinant live oral cholera vaccine, in: Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial and Viral Diseases. Cold Spring Harbor Laboratories, 1985, pp 107-111.

    Google Scholar 

  164. Glass RI, Holmgren J, Haley CE, et al: Predisposition for cholera of individuals with O blood group. Am J Epidemiol 121: 791–796, 1985.

    PubMed  CAS  Google Scholar 

  165. Levine MM, Nalin DR, Renneis MB, et al: Genetic susceptibility to cholera. Ann Human Biol 6: 369–374, 1979.

    Article  CAS  Google Scholar 

  166. Ichinose Y, Yamomoto K, Nakasone N, et al: Enterotoxicity of El Tor-like hemolysin of non-01 Vibrio cholerae. Infect Immun 55: 1090-1093.

    Google Scholar 

  167. Madden JM, McCardell BA, Shah DB: Cytotoxin production by members of genus Vibrio. Lancet i: 1217–1218, 1984.

    Article  Google Scholar 

  168. Nishibuchi M, Seidler RJ, Rollins DM, et al: Vibrio factors cause rapid fluid accumulation in suckling mice. Appl Environ Microbiol 45: 228–231, 1983.

    PubMed  CAS  Google Scholar 

  169. O’Brien AD, Chen ME, Holmes RK, et al: Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga-like) cytotoxin. Lancet i: 77–78, 1984.

    Article  Google Scholar 

  170. Sanyal SC, Neogi PKB, Alam K, et al: A new enterotoxin produced by Vibrio cholerae 01. J Diar Dis Res 2: 3–12, 1984.

    CAS  Google Scholar 

  171. Yamamoto K, Ichinose Y, Nakasone N, et al: Identity of hemolysins produced by Vibrio cholerae non-01 and V. cholerae 01, biotype El Tor. Infect Immun 51: 927–931, 1986.

    PubMed  CAS  Google Scholar 

  172. Yamamoto K, Maliha A-O, Honda T, et al: Non-01 Vibrio cholerae hemolysin: purification, partial characterization, and immunological relatedness to El Tor hemolysin. Infect Immun 45: 192-196.

    Google Scholar 

  173. Richardson K, Michalski J, Kaper JB: Hemolysin production and cloning of two hemolysin determinants from classical Vibrio cholerae. Infect Immun 54: 415–420, 1986.

    PubMed  CAS  Google Scholar 

  174. Levine MM, Kaper JB, Herrington D, et al: Safety, immunogenicity and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet ii: 467–470, 1988.

    Article  Google Scholar 

  175. Cryz SJ, Levine MM, Kaper JB, et al: Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine in press, 1990.

    Google Scholar 

  176. Migasena S, Pitisuttitham P, Prayurahong B, et al: Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun 57: 3261–3264, 1989.

    PubMed  CAS  Google Scholar 

  177. Forrest BD, LaBrooy JR, Attridge SR, et al: Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans. J Infect Dis 159: 145–146, 1989.

    Article  PubMed  CAS  Google Scholar 

  178. Formal SB, Baron LS, Kopecko DJ, et al: Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galESalmonella typhi Ty21a typhoid vaccine strain. Infect Immun 34: 746–750, 1981.

    PubMed  CAS  Google Scholar 

  179. Clements JD, E1-Morshidy S: Construction of a potential live oral bivalent vaccine for typhoid fever and cholem-Escherichia coli-related diarrheas. Infect Immun 46: 564–569, 1984.

    PubMed  CAS  Google Scholar 

  180. Tacket CO, Forrest B, Morona R, et al: Safety, immunogenicity and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi. Infect Immun 58: 1620–1627, 1990.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Myron M. Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathaniel F. Pierce
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Formerly of the School of Tropical Medicine, Calcutta, India

    Dhiman Barua

  2. Formerly of the Diarrhoeal Diseases Control Programme, World Health Organization, Geneva, Switzerland

    Dhiman Barua

  3. The Johns Hopkins University, Baltimore, Maryland, USA

    William B. Greenough III

  4. Formerly of the International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh

    William B. Greenough III

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Levine, M.M., Pierce, N.F. (1992). Immunity and Vaccine Development. In: Barua, D., Greenough, W.B. (eds) Cholera. Current Topics in Infectious Disease. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9688-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9688-9_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9690-2

  • Online ISBN: 978-1-4757-9688-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation